Raphael Nir, PhD
Co-Founder, Head of Preclinical Development
Raphael is a scientist, entrepreneur and angel investor with 27 years of biotechnology experience spanning preclinical research, drug discovery, cell-based assays, process development and recombinant cytokines production.
He is founder and owner of SBH Sciences, which he built from the ground up to become a leading supplier of recombinant cytokines and a preferred discovery research organization that has assisted more than 180 biotechnology companies since 1997. Raphael also co-founded the biotechnology companies Karyopharm Therapeutics (NASDAQ: KPTI), Galectin Sciences and Alma Bio Therapeutics, is co-founder of SBH Diagnostics, and co-founder and partner at Sky Ventures, Woodland Biosciences and ABI-LAB.
Raphael earned his Ph.D. in biotechnology his M.S. in biochemistry, and his B.S. in chemistry from Tel-Aviv University and his M.S. in engineering management from New Jersey Institute of Technology. He was a postdoctoral researcher at Schering Plough Research Institute where he later became a Senior Scientist/Associate Principal Scientist and developed innovative cell culture processes and solutions related to biological production.